Progestagen Type in Postmenopausal Hormone Therapy and Blood Gene Expression Profile

Inclusion Criteria: * Postmenopausal women defined as: * 45 years\< age \< 65 years * Amenorrhoeic for ≥ 1 year * Amenorrhoeic for \< 1 year either without any withdrawal vaginal bleeding for 3 consecutive months in spite of a cyclic progestagen treatment and/or blood estradiol levels ≤ 20 pg/mL and blood FSH levels ≥ 40 UI/mL * Women with bilateral ovariectomy * Women suffering of at least 1 postmenopausal symptoms listed: * Hot flashes, * Memory and Concentration Problems, * Mood Swings, * Insomnia, * Urinary Incontinence, * Night sweating, * Join pains, * Asthenia. * No use of hormone therapy (HT) * Previous HT user: * HT use \< 3 months - stop for 6 months * HT use \<= 1 year - stop for \> 12 months * If previous use of soya derivatives in dietary supplements: washout period = 3 months * Signed informed consent, after having received both oral- and written- information regarding the study goals, its risks and benefits and its constraints, including the 12 month follow-up. A delay should be respected between information and the signature of the written consent. Exclusion Criteria: * Past HT users who have used treatment for more than 1 year * Hysterectomized women * Women without health insurance (only in French centre) * History of cardio-vascular accident either arterial or venous * Untreated high blood pressure * Liver disease * Diabetes * History of cancer except basal-cell skin cancer and colon cancer * Severe history of familial breast cancer defined as at least 2 women first degree- relatives with breast cancer diagnosis before 50 years * History of severe mastalgia * History of breast biopsy showing hyperplasia (with or without atypia) * Undiagnosed vaginal bleeding * Diagnosed endometrial hyperplasia * Auto-immune disease (e.g. lupus) * Women with kidney transplant